BIOLASE (NASDAQ:BIOL – Get Free Report) issued its earnings results on Thursday. The medical technology company reported ($0.08) earnings per share for the quarter, reports. BIOLASE had a negative net margin of 43.56% and a negative return on equity of 1,782.73%. The business had revenue of $11.56 million for the quarter.
BIOLASE Trading Down 15.3 %
Shares of BIOL traded down $0.01 on Friday, reaching $0.05. 504,585 shares of the company’s stock were exchanged, compared to its average volume of 3,149,534. The stock has a market capitalization of $1.70 million, a P/E ratio of 0.00 and a beta of 0.71. The business has a 50 day moving average price of $0.10 and a two-hundred day moving average price of $0.19. BIOLASE has a 12 month low of $0.04 and a 12 month high of $6.70.
Institutional Investors Weigh In On BIOLASE
A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC boosted its position in shares of BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 143,537 shares of the medical technology company’s stock after purchasing an additional 131,248 shares during the quarter. Virtu Financial LLC owned 0.43% of BIOLASE worth $27,000 as of its most recent SEC filing. 8.79% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
View Our Latest Report on BIOL
BIOLASE Company Profile
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Further Reading
- Five stocks we like better than BIOLASE
- The 3 Best Retail Stocks to Shop for in August
- MarketBeat Week in Review – 8/5 – 8/9
- How to Use the MarketBeat Stock Screener
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- High Flyers: 3 Natural Gas Stocks for March 2022
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.